



This is a repository copy of *Low expression and promoter hypermethylation of the tumour suppressor SLIT2, are associated with adverse patient outcomes in diffuse large B cell lymphoma.*

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/142626/>

Version: Supplemental Material

---

**Article:**

Mohamed, G. [orcid.org/0000-0002-5831-4083](https://orcid.org/0000-0002-5831-4083), Talima, S., Li, L. et al. (6 more authors) (2019) Low expression and promoter hypermethylation of the tumour suppressor SLIT2, are associated with adverse patient outcomes in diffuse large B cell lymphoma. *Pathology & Oncology Research*, 25 (3). pp. 1223-1231. ISSN 1219-4956

<https://doi.org/10.1007/s12253-019-00600-9>

---

This is a post-peer-review, pre-copyedit version of an article published in *Pathology & Oncology Research*. The final authenticated version is available online at:  
<https://doi.org/10.1007/s12253-019-00600-9>.

**Reuse**


Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.




[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>




**Fig. 1: SLIT2 protein expression in normal lymphoid tissue and DLBCL primary tumours (a)** High SLIT2 protein expression in the reactive GCs, also in normal squamous epithelium of the tonsil, with low expression in few scattered interfollicular cells (Mag. 10x). **(b)** Higher magnification of one of the GCs expressing high SLIT2 protein. **(c)** Example of high SLIT2 expression (score 3) in DLBCL, sparing the residual normal/reactive lymphocytes. **(d)** A representative case of DLBCL with low SLIT2 expression (score 1).


A)




B)



**Fig. 2: Kaplan-Meier survival analysis for DLBCL cases expressing low/high SLIT2 protein. (A)** Low SLIT2 protein expression correlates with poor OS in DLBCL patients ( $p= 0.044$ ). **(B)** Patients with low SLIT2 protein or negative expression show difference in Event-free survival with a median of only 12.6 months as compared to 88.9 median survival of patients experienced high SLIT2 protein, however that was not statistically significant ( $p= 0.108$ ).



**Fig. 3: Re-analysis of a previously published gene expression dataset GSE10846.** High SLIT2 gene expression correlates with better overall survival in R-CHOP treated ABC DLBCL patients ( $p = < 0.01$ ).



**Fig. 4: Methylation-specific PCR (MSP) analysis of the SLIT2 promotor in microdissected GC B cells and DLBCL samples. (A)** DLBCL cases with variable SLIT2 protein intensities as detected by IHC. Samples highlighted in red express a low/negative SLIT2 protein. Reduced SLIT2 protein expression correlates with promotor methylation status (strong/moderate) ( $p=0.009$ ). **(B)** GC B cells expressing high SLIT2 protein show un-methylated status. Methylated (OCI-LY3) and unmethylated (HEK293) cell lines were used as positive controls. M: methylated; U: unmethylated